首页> 中文期刊>生命科学研究 >Legumain在恶性肿瘤中的研究现状

Legumain在恶性肿瘤中的研究现状

     

摘要

Legumain是一种溶酶体半胱氨酸蛋白酶,是半胱氨酸蛋白酶C13家族的新成员.研究表明,Legumain 作为一种应激性蛋白,在多种实体瘤、肿瘤相关巨噬细胞(TAMs)、肿瘤新生血管的内皮细胞中高表达,与恶性肿瘤的血管生成、肿瘤侵袭、扩散和转移密切相关,是近年来备受关注的一类靶标蛋白酶.对Legumain的深入研究将有利于阐明恶性实体瘤的发病机制,明确其作为肿瘤基因治疗新靶标的有效性.%The Legumain is a lysosomal proteinase belonging to a novel member of the C13 family of cys-teine proteases. Legumain, as a stress protein, has been reported to be overexpressed in the majority of human solid tumors, particularly in tumor-associated macrophages (TAMs) and tumor endothelial cells. Its over-expression is believed to associated with malignant tumor invasion, proliferation and metastasis, which makes Legumain attract much attention recently, as a candidate enzymatic target. Further studies on Legumain may provide us new insights into pathopaysiology processes of solid tumors, and help us evaluate its efficacy as a promising biomarker for cancer gene therapy.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号